Gastrointestinal Angiodysplasia: Management When Pharmacological Therapy Has Not Controlled Bleeding
When initial pharmacological therapy does not achieve cessation of bleeding or prevent rebleeding within target thresholds, a defined second-line approach is indicated. This protocol addresses that specific clinical situation.
First-line treatment with pharmacological therapy — including octreotide, thalidomide, or female sex hormones — did not achieve the required goals: cessation of bleeding, prevention of rebleeding, and stabilisation of hemoglobin and hematocrit within acceptable limits.
The next step centres on an endoscopic intervention to directly target the malformed vessels and achieve hemostasis; the specific modality and full decision algorithm are detailed in the complete protocol.
Cessation of active bleeding and prevention of rebleeding, with hemoglobin and hematocrit remaining stable within defined thresholds.
References
DOI: 10.1002/14651858.CD014582.
- Endoscopic management choices include Argon plasma coagulation, bipolar electrocoagulation, endoscopic resection, monopolar electrocoagulation, heater probe coagulation, laser photocoagulation, mechanical hemostasis, neodymium doped yttrium aluminum garnet, sclerotherapy, and cryotherapy.
- Novel endoscopic options for the management of angiodysplasia are continuously being developed, including techniques such as radiofrequency ablation, and the application of newer topical hemostatic agents, e.g. TC-325.
- Given that a significant portion of people with GI angiodysplasia are elderly, and often have comorbidities, it is advisable to approach endoscopic interventions cautiously, typically reserving them as a second-line therapy.
- Nevertheless, management is mainly assessed based on the cessation of bleeding, prevention of rebleeding, and improvement in a person's clinical status.
- Stability of hemoglobin/hematocrit levels: no further drop beyond 1 g/dL for hemoglobin and 5% for hematocrit following the intervention